ReportWire

Tag: HFAC1

  • Russian charged with war crimes may brief U.N. Security Council

    Russian charged with war crimes may brief U.N. Security Council

    UNITED NATIONS, April 3 (Reuters) – Russia’s commissioner for children’s rights, who is wanted by the International Criminal Court on war crimes charges, is likely to brief an informal meeting of the U.N. Security Council this week, according to a note seen by Reuters on Monday.

    Russia, which holds the monthly rotating presidency of the 15-member body for April, told council members in a note that it plans to hold an informal meeting on Wednesday on Ukraine, focused on “evacuating children from conflict zone.”

    “Participants will hear ‘first hand’ information from the Presidential Commissioner for Children’s Rights of the Russian Federation, as well as from children evacuated from the conflict area,” read the note.

    The commissioner is Maria Lvova-Belova. The International Criminal Court (ICC) last month issued an arrest warrant against Russian President Vladimir Putin and Lvova-Belova, accusing them of illegally deporting hundreds of children from Ukraine, as well as the unlawful transfer of people to Russia from Ukraine since Moscow invaded on Feb. 24, 2022.

    “They cannot invite a credible briefer because they do not have any credibility on this issue,” Britain’s Deputy U.N. Ambassador James Kariuki told Reuters in a statement. “Russian leaders have been charged by the ICC with unlawfully deporting children from Ukraine to Russia. That is a war crime.”

    Russia’s U.N. Ambassador Vassily Nebenzia said on Monday that the meeting briefers would be announced shortly. Such meetings are held at U.N. headquarters, but not in the Security Council chamber, and briefings can be done virtually.

    ‘APRIL FOOL’S JOKE’

    Moscow has not concealed a program under which it has brought thousands of Ukrainian children to Russia but presents it as a humanitarian campaign to protect orphans and children abandoned in the conflict zone.

    Nebenzia told reporters last month that the informal meeting of Security Council members to be held on Wednesday had been planned long before the ICC announcement and it was not intended to be a rebuttal of the charges against Putin and Lvova-Belova.

    While a feature of Russia’s presidency, members do not need to be the rotating monthly president to hold such meetings.

    Russian Foreign Minister Sergei Lavrov is due to travel to New York to chair formal Security Council meetings later in the month on the Middle East and on “effective multilateralism through the defense of the principles of the U.N. Charter.”

    The 193-member U.N. General Assembly has criticized Russia for violating the founding U.N. Charter by invading its neighbor and called for a “comprehensive, just and lasting peace” in line with the principles of the U.N. Charter.

    Given Russia’s Security Council presidency started on April 1, U.S. Ambassador to the United Nations, Linda Thomas-Greenfield, told reporters on Monday: “It’s like an April Fool’s joke … We expect that they will behave professionally.”

    “But we also expect that they will use their seat to spread disinformation and to promote their own agenda as it relates to Ukraine, and we will stand ready to call them out at every single moment that they attempt to do that,” she said.

    Reporting by Michelle Nichols; Editing by Don Durfee and Bill Berkrot

    Our Standards: The Thomson Reuters Trust Principles.

    Source link

  • U.S. FDA allows abortion pills to be sold at retail pharmacies

    U.S. FDA allows abortion pills to be sold at retail pharmacies

    WASHINGTON, Jan 3 (Reuters) – The U.S. Food and Drug Administration (FDA) will allow retail pharmacies to offer abortion pills in the United States for the first time, the agency said on Tuesday, even as more states seek to ban medication abortion.

    The regulatory change will potentially expand abortion access as President Joe Biden’s administration wrestles with how best to protect abortion rights after they were sharply curtailed by the Supreme Court’s decision to overturn the landmark Roe v Wade ruling and the state bans that followed.

    Pharmacies can start applying for certification to distribute abortion pill mifepristone with one of the two companies that make it, and if successful they will be able to dispense it directly to patients upon receiving a prescription from a certified prescriber.

    The FDA had first said it would be making those changes in December 2021 when it announced it would relax some risk evaluation and mitigation strategies, or REMS, on the pill, that had been in place since the agency approved it in 2000 and were lifted temporarily in 2021 due to the COVID-19 pandemic.

    The changes included permanently removing restrictions on mail order shipping of the pills and their prescription through telehealth.

    The agency finalized the changes on Tuesday after reviewing supplemental applications from Danco Laboratories and GenBioPro, the two companies that make the drug in the United States.

    “Under the Mifepristone REMS Program, as modified, Mifeprex and its approved generic can be dispensed by certified pharmacies or by or under the supervision of a certified prescriber,” the agency said on its website on Tuesday.

    Mifeprex is the brand name version of mifepristone which, in combination with a second drug called misoprostol that has various uses including miscarriage management, induces an abortion up to 10 weeks into a pregnancy in a process known as medication abortion.

    Abortion rights activists say the pill has a long track record of being safe and effective, with no risk of overdose or addiction. In several countries, including India and Mexico, women can buy them without a prescription to induce abortion.

    “Today’s news is a step in the right direction for health equity,” Planned Parenthood President Alexis McGill Johnson said in a statement.

    “Being able to access your prescribed medication abortion through the mail or to pick it up in person from a pharmacy like any other prescription is a game changer for people trying to access basic health care,” Johnson added.

    NO EQUAL ACCESS

    The regulatory change will, however, not provide equal access to all people, GenBioPro, which makes the generic version of mifepristone, said in a statement.

    Abortion bans, some targeting mifepristone, have gone into effect in more than a dozen states since the U.S. Supreme Court overturned the constitutional right to terminating pregnancies when it scrapped the 1973 Roe v. Wade ruling last year.

    Women in those states could potentially travel to other states to obtain medication abortion.

    The president of anti-abortion group SBA Pro-Life America, Marjorie Dannenfelser, said the latest FDA move endangers women’s safety and the lives of unborn children.

    “State lawmakers and Congress must stand as a bulwark against the Biden administration’s pro-abortion extremism,” she said in a statement.

    FDA records show a small mortality case number associated with mifepristone. As of June 2021, there were reports of 26 deaths linked with the pill out of 4.9 million people estimated to have taken it since it was approved in September 2000.

    Retail pharmacies will have to weigh whether or not to offer the pill given the political controversy surrounding abortion, and determine where they can do so.

    A spokesperson for CVS Health (CVS.N) said the drugstore chain owner was reviewing the updated REMS “drug safety program certification requirements for mifepristone to determine the requirements to dispense in states that do not restrict the dispensing of medications prescribed for elective termination of pregnancy.”

    A spokesperson for Walgreens (WBA.O), one of the largest U.S. pharmacies, said the company was also reviewing the FDA’s regulatory change. “We will continue to enable our pharmacists to dispense medications consistent with federal and state law.”

    Reporting by Ahmed Aboulenein; Additional reporting by Eric Beech in Washington, Shivani Tanna, Rahat Sandhu, and Kanjyik Ghosh in Bengaluru; Editing by Himani Sarkar

    Our Standards: The Thomson Reuters Trust Principles.

    Ahmed Aboulenein

    Thomson Reuters

    Washington-based correspondent covering U.S. healthcare and pharmaceutical policy with a focus on the Department of Health and Human Services and the agencies it oversees such as the Food and Drug Administration, previously based in Iraq and Egypt.

    Source link